论文部分内容阅读
目的评价美沙拉嗪口服联合麦滋林保留灌肠治疗轻、中度溃疡性结肠炎(UC)的临床疗效及安全性。方法选择确诊为轻、中度UC患者48例,随机分为治疗组和对照组各24例。治疗组口服美沙拉嗪1.0g,3次/d,美沙拉嗪2.0g及麦滋林2.01g加入0.9%氯化钠注射液100ml中保留灌肠,每晚1次;对照组口服美沙拉嗪1.0g,3次/d。疗程均为4周。结果治疗组临床总有效率为95.8%(23/24),对照组为75.0%(18/24),2组比较差异有统计学意义(P<0.05);结肠镜检查各项指标改善情况,治疗组总缓解率为91.7%(22/24),对照组为83.3%(20/24),2组差异无统计学意义(P>0.05);治疗组和对照组不良反应发生率分别为16.7%和12.5%,无严重不良反应事件发生。结论美沙拉嗪在轻、中度UC的治疗中能够取得良好的疗效,联合麦滋林及美沙拉嗪保留灌肠能够提高其有效率,且不良反应无明显升高。该方法是治疗轻、中度UC较理想且安全的方法。
Objective To evaluate the clinical efficacy and safety of mesalazine oral combined with MaiZhulin retention enema in the treatment of mild and moderate ulcerative colitis (UC). Methods Forty-eight patients diagnosed as mild to moderate UC were randomly divided into treatment group (24 cases) and control group (24 cases). The treatment group oral mesalazine 1.0g, 3 times / d, Mesalazine 2.0g and Mai Zuolin 2.01g added 0.9% sodium chloride injection 100ml retention enema, 1 night; the control group oral mesalazine 1.0 g, 3 times / d. The course of treatment is 4 weeks. Results The total effective rate was 95.8% (23/24) in the treatment group and 75.0% (18/24) in the control group. The difference between the two groups was statistically significant (P <0.05). The improvement of various indexes of colonoscopy, The total remission rate was 91.7% (22/24) in the treatment group and 83.3% (20/24) in the control group, with no significant difference between the two groups (P> 0.05). The incidences of adverse reactions in the treatment group and the control group were 16.7 % And 12.5%, no serious adverse event occurred. Conclusion Mesalazine can achieve good curative effect in the treatment of mild and moderate UC. The combination of mesalamine and mesalazine retention enema can improve its efficiency and the adverse reaction is not obviously increased. This method is a more ideal and safe way to treat mild to moderate UC.